Price
No data yet.
Social Signal Score
Analyst Ratings
27 analystsRevenue
$65.00M+6742.11%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Nello Mainolfi
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 273
- Beta
- 1.98
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 36.58
Financials
Revenue
$65.00M+6742.1%Net Income
$-61.21MEBITDA
$-59.10MFree Cash Flow
$-54.54MEPS (diluted)
$-0.62Shares Outstanding (diluted)
98.18M+120.5%Operating Expenses
$140.61MCash & Debt
$690.99MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $39.20M | $-311.40M | $-3.69 |
| 2024 | $47.07M | $-223.86M | $-2.98 |
| 2023 | $78.59M | $-146.96M | $-2.52 |
| 2022 | $46.83M | $-154.81M | $-2.87 |
| 2021 | $72.83M | $-100.22M | $-2.09 |
| 2020 | $34.03M | $-45.59M | $-0.99 |
| 2019 | $2.93M | $-41.29M | $-0.93 |
| 2018 | $0.00 | $-21.47M | $-0.48 |
Valuation
KYMRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (7)
- News (RSS)seekingalpha·9d ago·Neutral
Kymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon
View source ↗ - Newsseekingalpha.com·33d ago·Positive
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (Marketaux)gurufocus.com·34d ago·Positive
KYMR Maintained by B of A Securities -- Price Target Raised to $144 Kymera Therapeutics: A[+238 characters]
View source ↗ - Newszacks.com·44d ago·Neutral
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·45d ago·Neutral
Can KT-621 Mark a Turning Point for Kymera Therapeutics? KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Kymera Therapeutics to Participate in Upcoming September Investor Conferences WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 21st Annual Healthcare Conference in Boston, MA on…
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
…READTH Phase 2b asthma trial ongoing, with topline data expected in late 2027 WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present two posters featuring previously reported data from the BroADen Phase 1b trial evaluating KT-621, its first-in-class, oral STAT6 degrader, in pati…
View source ↗
Earnings
Tue, Nov 3(in 2 weeks)
Consensus estimate $-1.27 per share
Typical surprise -14.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.62 vs $-0.71beat
- Thu, Apr 30$-0.71 vs $-0.89beat
- Thu, Feb 26$-0.97 vs $-0.78miss
- Tue, Nov 4$-0.90 vs $-0.71miss
- Mon, Aug 11$-0.95 vs $-0.83miss
- Fri, May 9$-0.82 vs $-0.92beat
Estimates and results for KYMR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KYMR officers and directors.
- Bought
- —
- Sold
- $297.4m
0 trades
88 trades
- Mainolfi Nellosold
- Mainolfi Nellosold
- Mainolfi Nellosold
- Mainolfi Nellosold
- Mainolfi Nellosold
- Mainolfi Nellosold
- Adams Briansold
- Adams Briansold
12 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KYMR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.